The findings are being presented this week at the European Society of Cardiology congress, are from a sub-analysis of the Pegasus clinical trial, which first reported positive results in 2015.
The trial studied subjects who had a heart attack within the past one to three years and was designed to prove the value of extended use of Brilinta, which is a key product for AstraZeneca.
The sub-analysis also showed a risk reduction of 20 percent in all causes of death, while bleeding rates were consistent with the drug's safety profile, AstraZeneca said on Thursday.
This article was provided by Reuters.